PolyPid Announces New Publication Highlighting Antibacterial Activity Of D-PLEX Against Susceptible And Resistant Bacteria For The Prevention Of Surgical Site Infections
Portfolio Pulse from Benzinga Newsdesk
PolyPid has announced a new publication that highlights the antibacterial activity of D-PLEX against susceptible and resistant bacteria for the prevention of surgical site infections. The publication shows the potent antibacterial efficacy of D-PLEX100 in in-vivo and phase 2 clinical studies against a wide range of bacteria tested, including resistant strains.
June 29, 2023 | 12:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The new publication highlighting the antibacterial activity of PolyPid's D-PLEX could potentially increase investor confidence in the company and its products.
The publication of positive results from in-vivo and phase 2 clinical studies of D-PLEX100 could potentially increase investor confidence in PolyPid and its products. This could lead to increased demand for the company's stock, potentially driving up its price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100